AstraZeneca's vistusertib shows exciting results in ovarian and lung cancer

23 August 2018

An early clinical trial has shown AstraZeneca's (LSE: AZN) vistusertib, when combined with chemotherapy, as capable of causing shrinkage in ovarian and lung cancer in patients for whom other treatments have already failed.

The results, which represent a significant improvement over the current standard of care, show tumor shrinkage in half of patients suffering from ovarian cancer and more than a third of those suffering from lung cancer.

Results from the study, which was funded by AstraZeneca and carried out the Institute for Cancer Research (ICR) in London, were published on Wednesday in Annals of Oncology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK